Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

NCT07076706 is registered in ClinicalTrials.gov with Beijing Dayspring Pharmaceutical Technology Co., Ltd as lead sponsor.

NCT NCT07076706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07076706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
Lead sponsor
Beijing Dayspring Pharmaceutical Technology Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
December 5, 2024
Completion date
September 23, 2025
Enrollment
110 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

androgenetic alopecia (aga), male pattern of hair loss, androgenic alopecia